Would You Like To Book A SmartState Program Speaker?

Click Here

Dr. Igor Roninson 

Endowed Chair in Translational Cancer Therapeutics

Translational Cancer Therapeutics

    • Internationally recognized for cancer research, including his study of multi-drug resistance in cancer and chemotherapy-induced senescence in tumor cells.
    • Winner of the American Association for Cancer Research Award for Meritorious Achievement in Cancer Research
    • Recipient of the Life Extension Prize from the Regenerative Medicine Secretariat
    • Holds 44 U.S. patents
    • Founder, Senex Biotechnology, Inc., a drug discovery and development company
    • Awarded $1.5 million grant from the National Cancer Institute in 2011
  • CTT LogoAwarded $11.3 million grant from the National Institutes of Health to support the COBRE Center for Targeted Therapeutics at USC and MUSC (COBRE CTT). The Center supports the development of molecularly targeted drugs for the treatment of different diseases.

Dr. Igor Roninson is a groundbreaking researcher in cancer therapeutics whose work on the mechanisms of drug resistance has resulted in the development of new approaches to improving cancer chemotherapy and provided major insights in pharmacogenomics - the study of how an individual's genes affect the body's response to drugs. His principal research interests include developing personalized cancer therapy based on target and drug discovery through functional genomics; functional genomics of aging and longevity; chemical genomics of tumor microenvironment; mechanisms and pharmacological modulation of a damage-inducible signal transduction pathway implicated in cancer, Alzheimer’s disease and viral diseases. 

Dr. Roninson’s many research accomplishments in the cancer field include chemotherapy-induced senescence in tumor cells. (COBRE CTT)

Dr. Roninson is the President and Chief Scientific Officer of Senex Biotechnology Inc., which he relocated to Columbia, SC, when he accepted his SmartState Endowed Chair. The company focuses on the discovery and development of novel classes of anticancer drugs aimed at molecular targets identified through Dr. Roninson's research; some of the drugs may also have utility in age-related diseases other than cancer.

A prolific researcher and innovator, Dr. Roninson holds 44 U.S. patents and has authored more than 165 articles. He has tenure at both the University of South Carolina and the Medical University of South Carolina (MUSC).

Connect With SmartState Endowed Chairs To Learn About Their Research And Business Development Opportunities

Click Here